Last updated: September 4, 2026
Betrixaban, marketed as Bevyxxa by Portola Pharmaceuticals, was approved by the U.S. Food and Drug Administration in 2017 for extended-duration venous thromboembolism prevention in acutely ill hospitalized adults. The product failed to establish a durable commercial position against entrenched direct oral anticoagulants and low-molecular-weight heparin. Alexion discontinued U.S. commercial operations for Bevyxxa after acquiring Portola, leaving betrixaban with no meaningful active commercial market in the United States.
What is betrixaban and what was it approved to treat?
Betrixaban is an oral, direct factor Xa inhibitor. Its FDA-approved indication covered the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness who had risk factors for thromboembolic complications and who were at risk of complications from prolonged immobilization.
The approved regimen was distinctive:
| Product |
Active ingredient |
Approved use |
Typical treatment duration |
| Bevyxxa |
Betrixaban maleate |
Extended VTE prophylaxis after hospitalization for acute medical illness |
35 to 42 days |
| Eliquis |
Apixaban |
VTE treatment, prophylaxis, atrial fibrillation |
Indication-dependent |
| Xarelto |
Rivaroxaban |
VTE treatment and prophylaxis, atrial fibrillation |
Indication-dependent |
| Lovenox |
Enoxaparin |
Inpatient VTE prophylaxis and treatment |
Usually inpatient or short-term |
| Pradaxa |
Dabigatran |
VTE treatment and atrial fibrillation |
Indication-dependent |
Betrixaban was designed to address post-discharge VTE risk, a period in which many patients remained immobile but were no longer receiving inpatient anticoagulant prophylaxis. Its commercial proposition depended on demonstrating that physicians would extend anticoagulation beyond the hospital stay.
When did the FDA approve betrixaban?
The FDA approved Bevyxxa on June 23, 2017. The approval was based primarily on the APEX Phase 3 trial, which evaluated extended-duration betrixaban against standard-duration enoxaparin followed by placebo in acutely ill medical patients.
The APEX study produced a mixed commercial and clinical message. Betrixaban reduced VTE events in certain prespecified populations, but the broad primary endpoint did not produce the type of unequivocal result generally needed to change routine hospital anticoagulation practice. The label therefore reflected a narrower, risk-selected use case rather than a universal post-discharge prophylaxis indication.
Key regulatory milestones were:
| Date |
Event |
| 2017 |
FDA approval of Bevyxxa |
| 2017 |
U.S. commercial launch by Portola |
| 2020 |
Alexion completed acquisition of Portola for approximately $1.4 billion |
| 2020-2021 |
Commercial prioritization shifted toward Alexion’s rare-disease portfolio and Andexxa |
| 2021 |
Bevyxxa commercial availability ended in the United States |
| Current status |
No meaningful U.S. commercial market for betrixaban |
Sources: FDA, 2017; Portola Pharmaceuticals, 2020; Alexion Pharmaceuticals, 2021.
What drove betrixaban’s weak market performance?
Betrixaban entered a market controlled by drugs with broader indications, stronger physician familiarity, and larger commercial infrastructure.
Narrow indication and complex positioning
Betrixaban was not approved for atrial fibrillation stroke prevention or for the general treatment of established VTE. Those indications drive a large share of direct oral anticoagulant prescribing. Betrixaban instead targeted a narrower segment: acutely ill medical inpatients requiring extended prophylaxis after discharge.
That segment had several commercial constraints:
- The number of eligible patients was substantial, but treatment duration was limited.
- Hospital formularies already used inexpensive enoxaparin for routine prophylaxis.
- Physicians had to balance post-discharge VTE risk against bleeding risk.
- Discharge protocols were not consistently designed for extended anticoagulant prescribing.
- Eliquis and Xarelto already had extensive clinical familiarity and payer access.
- Generic and low-cost parenteral alternatives reduced the price ceiling.
Competitive disadvantage versus established factor Xa inhibitors
Betrixaban shared a mechanism with apixaban and rivaroxaban but lacked their indication breadth. The leading products could be prescribed across multiple disease states, allowing manufacturers to support larger sales forces, broader payer contracting, and stronger guideline penetration.
Betrixaban’s once-daily dosing and limited renal clearance were potential advantages. Those attributes did not overcome the absence of a broader treatment franchise.
Evidence did not create a clear standard of care
The APEX evidence supported use in selected high-risk hospitalized patients, but it did not establish betrixaban as the default extended-prophylaxis choice across the full acutely ill population. Competing clinical guidelines and hospital protocols continued to favor risk stratification, inpatient prophylaxis, or established anticoagulants with more extensive use histories.
What was betrixaban’s financial trajectory?
Betrixaban did not become a material revenue contributor to Portola. The company’s financial profile was dominated by Andexxa, its factor Xa inhibitor reversal agent, and by research and development costs associated with its broader pipeline.
Portola’s betrixaban economics were constrained by:
- Limited prescribing volume.
- Short treatment courses.
- High launch and market-access costs.
- Competition from low-cost enoxaparin.
- Competition from larger anticoagulant franchises.
- Lack of a second major indication.
- The need to maintain a commercial infrastructure for a single narrow-use product.
Portola’s acquisition by Alexion was driven primarily by Andexxa and the strategic value of Portola’s reversal-agent platform, not by Bevyxxa’s standalone growth prospects. After the acquisition, management concentrated resources on rare-disease operations and Andexxa commercialization. Betrixaban did not receive the level of investment required to reposition it against established oral anticoagulants.
| Financial factor |
Effect on betrixaban |
| Product sales |
Low relative to leading direct oral anticoagulants |
| Gross-margin potential |
Mechanically favorable as an oral small molecule, but offset by low volume |
| Commercial spending |
Difficult to justify for a narrow indication |
| Reimbursement |
Dependent on hospital and post-discharge coverage |
| Portfolio value |
Secondary to Andexxa in the Portola transaction |
| Long-term revenue outlook |
Effectively terminated in the U.S. after commercial withdrawal |
Public company filings did not present Bevyxxa as a major standalone growth asset. Its commercial discontinuation eliminated future U.S. product revenue and removed the need for a large ongoing sales and marketing program.
What patents protected betrixaban?
Betrixaban was protected through a combination of compound, formulation, and use-related intellectual property developed by Portola and earlier research organizations. The relevant estate included patents covering the factor Xa inhibitor chemical class, betrixaban compositions, pharmaceutical formulations, and treatment or prophylaxis applications.
Patent value was limited by the product’s commercial withdrawal. A patent estate can preserve exclusionary rights, but it cannot create demand where the product lacks a durable reimbursement and prescribing position.
Compound and formulation protection
The principal technical barriers involved:
- Betrixaban and related factor Xa inhibitor compounds.
- Pharmaceutically acceptable salts, including betrixaban maleate.
- Oral dosage forms.
- Pharmaceutical compositions and dosage regimens.
- Methods for preventing or treating thromboembolic disease.
Patent term was affected by filing dates, patent-term adjustment, patent-term extension, terminal disclaimers, and the specific claims surviving prosecution and litigation. The commercial significance of any remaining U.S. patent term declined sharply after withdrawal.
Orange Book and generic entry
Bevyxxa was listed in the FDA’s Orange Book during its commercial life. Because betrixaban is a small-molecule drug, the relevant generic pathway was an abbreviated new drug application, not a biosimilar application.
A generic applicant could have pursued a Paragraph IV certification against listed patents. No Paragraph IV challenge became a material market event comparable to the challenges involving high-value anticoagulants such as Eliquis or Xarelto.
The withdrawal of the reference product reduced the economic incentive to fund an aggressive generic launch. Generic entry is commercially rational when the market supports sufficient volume and pricing. Betrixaban’s narrow indication and discontinued brand weakened that incentive.
Are there biosimilar risks for betrixaban?
No. Betrixaban is a chemically synthesized small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply.
The relevant competitive risks were:
- Abbreviated new drug applications.
- Authorized generic or alternative small-molecule products.
- Therapeutic substitution by apixaban, rivaroxaban, or enoxaparin.
- Hospital protocol changes.
- Loss of formulary position.
In practical terms, therapeutic substitution was more important than formal generic competition. Physicians and payers could meet the same clinical need with existing anticoagulants without waiting for a betrixaban generic.
What patent litigation and settlement agreements affected betrixaban?
No major betrixaban patent litigation or Paragraph IV settlement became a defining commercial event in the U.S. market. The product’s principal failure was commercial rather than litigation-driven.
That distinction matters. Products such as Eliquis and Xarelto generated extensive patent litigation because their revenue bases justified prolonged challenges and settlements. Betrixaban’s limited sales did not create comparable litigation economics.
The absence of major litigation did not indicate a weak chemical patent position. It indicated that the expected return from challenging or defending the asset was limited.
How does betrixaban compare with Eliquis and Xarelto?
| Measure |
Betrixaban |
Eliquis |
Xarelto |
| Core class |
Direct factor Xa inhibitor |
Direct factor Xa inhibitor |
Direct factor Xa inhibitor |
| Major use |
Extended VTE prophylaxis in selected medical patients |
Atrial fibrillation, VTE treatment and prevention |
Atrial fibrillation, VTE treatment and prevention |
| Commercial breadth |
Narrow |
Broad |
Broad |
| Post-discharge prophylaxis |
Central product concept |
Not the primary franchise identity |
Broader prophylaxis presence |
| Generic pressure |
Limited commercial challenge |
Major patent and generic-entry focus |
Major patent and generic-entry focus |
| Market outcome |
Withdrawn |
Large global franchise |
Large global franchise |
| Strategic durability |
Low |
High |
High |
Betrixaban illustrates that mechanistic similarity does not produce commercial parity. Indication breadth, clinical familiarity, payer coverage, hospital integration, and lifecycle management were more important than once-daily dosing alone.
What generic launch risks exist today?
The direct generic-launch risk is low because the U.S. reference product is no longer an active commercial franchise. The more significant risk to any revived betrixaban program would come from therapeutic competition.
A new sponsor would face:
- Re-establishing FDA and commercial positioning.
- Generating contemporary evidence for extended prophylaxis.
- Securing hospital and payer adoption.
- Competing with established factor Xa inhibitors.
- Addressing bleeding-risk concerns.
- Funding a sales infrastructure for a narrow indication.
- Demonstrating differentiation beyond renal clearance and dosing convenience.
A reintroduction would require more than patent freedom. It would require a new commercial thesis.
What is the outlook for betrixaban?
Betrixaban’s U.S. commercial outlook is effectively inactive. No major revenue recovery is visible without a new sponsor, a new indication, or materially differentiated clinical evidence.
The asset retains technical relevance as a selective oral factor Xa inhibitor, but its market value is constrained by the lack of a current commercial platform. Its strategic value would be higher as part of a broader anticoagulation or reversal portfolio than as a standalone prophylaxis product.
Key Takeaways
- Betrixaban was FDA-approved in 2017 as Bevyxxa for extended VTE prophylaxis in selected acutely ill medical patients.
- Its indication was narrower than those of Eliquis and Xarelto.
- The APEX evidence supported selected use but did not establish a broad standard of care.
- Portola’s financial performance was driven more by Andexxa than by Bevyxxa.
- Alexion acquired Portola primarily for Andexxa and related assets.
- Bevyxxa commercial operations ended in the United States around 2021.
- Betrixaban has no biosimilar risk because it is a small molecule.
- No major Paragraph IV litigation or settlement defined the product’s lifecycle.
- Current competitive risk comes from therapeutic substitution, not from a likely generic launch.
- A commercial revival would require new clinical differentiation and a broader market strategy.
FAQs
Is betrixaban still sold in the United States?
No. Bevyxxa is no longer a meaningful commercially marketed product in the United States.
Who owned Bevyxxa?
Portola Pharmaceuticals developed and commercialized Bevyxxa. Alexion Pharmaceuticals acquired Portola in 2020. Alexion was later acquired by AstraZeneca.
Did betrixaban compete directly with Eliquis?
Yes, but only in a limited clinical segment. Betrixaban competed with Eliquis and other anticoagulants for VTE prevention, while Eliquis had much broader use in atrial fibrillation and VTE treatment.
Was betrixaban’s failure caused by patent expiration?
No. Commercial weakness, limited indication breadth, clinical positioning, and competition were more important than patent expiry.
Could betrixaban return as a generic?
A generic could theoretically be developed if regulatory, patent, manufacturing, and commercial conditions permitted. The limited market size and availability of substitute anticoagulants make a large-scale launch economically unattractive.
References
-
Alexion Pharmaceuticals, Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Food and Drug Administration. (2017). FDA approves Bevyxxa to reduce the risk of blood clots in patients hospitalized for acute illness. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2017). Bevyxxa prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2021). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Portola Pharmaceuticals, Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., & Hernandez, A. F. (2016). Extended thromboprophylaxis with betrixaban in acutely ill medical patients. New England Journal of Medicine, 375(6), 534-544.
